Most importantly, also in this cohort we found that functional BCL-2 dependence of the leukemia cells measured by BAD-HRK priming is significantly associated with preclinical response (Fig. 4b) predicting in vivo antileukemia VEN activity, in both BCP- and T-ALL (Fig. 4c). The gene discussed is HRK; the disease is acute lymphoblastic leukemia.